002675 东诚药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入2,043,089-5.52%2,868,9373,275,6483,582,9553,912,050
减:营业总成本1,862,700-4.25%2,649,0522,826,4773,034,6453,349,520
    其中:营业成本1,016,318-13.69%1,516,5291,805,9582,044,3752,309,876
               财务费用91,40032.72%77,23431,2936,15157,990
               资产减值损失----(83,875)(111,886)(80,290)(217,321)
公允价值变动收益68518.19%1,068(19,474)4011,171
投资收益(10,265)41.37%(13,985)(8,654)(39,614)(13,325)
    其中:对联营企业和合营企业的投资收益(15,334)-23.08%(25,289)(37,751)(41,716)(19,962)
营业利润182,449-15.46%220,806341,662448,252356,932
利润总额181,665-15.28%219,103337,282445,576356,099
减:所得税费用57,110-9.01%77,67883,06592,74995,249
净利润124,555-17.87%141,425254,216352,828260,850
减:非控股权益(24,561)61.46%(42,401)44,48145,536109,288
股东净利润149,116-10.64%183,826209,736307,291151,561

市场价值指针
每股收益 (元) *0.181-10.67%0.2230.2540.3800.189
每股派息 (元) *----0.0800.1250.1500.150
每股净资产 (元) *5.303-2.85%5.4345.7915.759--
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容